Goss Franz, Brachmann Johannes, Hamm Christian W, Haerer Winfried, Reifart Nicolaus, Levenson Benny
Herzzentrum Alter Hof, München, Germany.
Klinikum Coburg GmbH, II. Medizinische Klinik, Coburg, Germany.
Vasc Health Risk Manag. 2017 Apr 6;13:127-137. doi: 10.2147/VHRM.S119490. eCollection 2017.
We aimed to assess patient acceptance and effectiveness of a 12-month structured management program in patients after an acute coronary syndrome (ACS) event who were treated in a special setting of office-based cardiologists. The program comprised patient documentation with a specific tool (Bundesverband Niedergelassener Kardiologen [German Federation of Office-Based Cardiologists] cardiac pass with visit scheduling) shared by the hospital physician and the office-based cardiologist, the definition of individual treatment targets, and the systematic information of patients in order to optimize adherence to therapy. Participating centers (36 hospitals, 60 office-based cardiologists) included a total of 1,003 patients with ACS (ST-segment elevation myocardial infarction [STEMI] 44.3%, non-ST-segment elevation myocardial infarction [NSTEMI] 39.5%, unstable angina pectoris [UA] 15.2%, and unspecified 1.0%). During follow-up, treatment rates with cardiac medication remained high in all groups, with dual antiplatelet therapy in 91.0% at 3 months, 90.0% at 6 months, and 82.8% at 12 months, respectively. Twelve months after the inclusion, a total of 798 patients (79.6%) still participated in the program. Eighteen patients (1.8%) had died after discharge from hospital (6 in the STEMI, 12 in the NSTEMI group), while for 58 the status was unknown (5.8%). Based on a conservative approach that considered patients with unknown status as dead, 1-year mortality was 7.6%. Recurrent cardiac events were noted in 14.9% at 1 year, with an about equal distribution across STEMI and NSTEMI patients. In conclusion, patients' acceptance of the ProAcor program as determined by adherence rates over time was high. Treatment rates of recommended medications used for patients with coronary heart disease were excellent. The 1-year mortality rate was comparatively low.
我们旨在评估一项为期12个月的结构化管理项目在急性冠状动脉综合征(ACS)事件后于专科门诊心脏病专家处接受治疗的患者中的患者接受度及有效性。该项目包括由医院医生和门诊心脏病专家共享的使用特定工具(德国门诊心脏病专家联合会心脏通行证及就诊安排)进行患者记录、确定个体治疗目标以及对患者进行系统宣教以优化治疗依从性。参与的中心(36家医院,60位门诊心脏病专家)共纳入了1003例ACS患者(ST段抬高型心肌梗死[STEMI]占44.3%,非ST段抬高型心肌梗死[NSTEMI]占39.5%,不稳定型心绞痛[UA]占15.2%,未明确类型占1.0%)。在随访期间,所有组中心脏药物的治疗率均保持较高水平,双联抗血小板治疗在3个月时为91.0%,6个月时为90.0%,12个月时为82.8%。纳入研究12个月后,共有798例患者(79.6%)仍参与该项目。18例患者(1.8%)出院后死亡(STEMI组有6例,NSTEMI组有12例),另有58例患者状态不明(5.8%)。基于将状态不明的患者视为死亡的保守方法,1年死亡率为7.6%。1年时复发性心脏事件发生率为14.9%,在STEMI和NSTEMI患者中的分布大致相等。总之,根据随时间推移的依从率确定,患者对ProAcor项目的接受度较高。用于冠心病患者的推荐药物治疗率极佳。1年死亡率相对较低。